Evidence map›Paper›PMID 37942495›Full record

ArticleBJR open2023

Transperineal laser ablation (TPLA) with ultrasound/MRI fusion guidance in the treatment of localized radiotherapy-resistant prostate cancer.

Guglielmo Manenti, Marco Nezzo, Colleen Patricia Ryan, Federico Romeo Fraioli, Beatrice Carreri, Paola Elda Gigliotti, Cecilia Angeloni, Francesca Di Pietro, Martina De Angeli, Tommaso Perretta and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BJR open, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Surgical Ablative Therapies in Patients With Radiorecurrent Prostate Cancer.Cancer control : journal of the Moffitt Cancer Center
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Guglielmo Manenti
Marco NezzoDepartment of Diagnostic Imaging and Interventional Radiology, University of Rome Tor Vergata, Rome, Italy.
Colleen Patricia RyanLaboratory of Neuromotor Physiology, IRCCS Fondazione Santa Lucia, Rome, Italy.
Federico Romeo FraioliDepartment of Diagnostic Imaging and Interventional Radiology, University of Rome Tor Vergata, Rome, Italy.
Beatrice CarreriDepartment of Diagnostic Imaging and Interventional Radiology, University of Rome Tor Vergata, Rome, Italy.
Paola Elda GigliottiDepartment of Diagnostic Imaging and Interventional Radiology, University of Rome Tor Vergata, Rome, Italy.ORCID https://orcid.org/0000-0001-7528-398X
Cecilia AngeloniDepartment of Diagnostic Imaging and Interventional Radiology, University of Rome Tor Vergata, Rome, Italy.
Francesca Di PietroDepartment of Diagnostic Imaging and Interventional Radiology, University of Rome Tor Vergata, Rome, Italy.
Martina De AngeliRadiotherapy Unit, Tor Vergata University Hospital of Rome, Rome, Italy.
Tommaso PerrettaDepartment of Diagnostic Imaging and Interventional Radiology, University of Rome Tor Vergata, Rome, Italy.
Rolando Maria D'AngelilloRadiotherapy Unit, Tor Vergata University Hospital of Rome, Rome, Italy.
Francesco Giuseppe GaraciDepartment of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.
University of Rome Tor Vergata · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: The objective of this study was to assess the technical feasibility, safety, and efficacy of transperineal laser ablation (TPLA) guided by ultrasound/magnetic resonance (MR) fusion as a salvage treatment for refractory focal prostate cancer. Methods: A total of five patients who had undergone radiation therapy (RT) for prostate carcinoma and biochemical recurrence, confirmed by both prostate-specific antigen (PSA) levels and MRI (3T mpMRI), were enrolled in this study. Focal ablation was performed using a 1064 nm diode laser. Post-ablation follow-up was conducted for a duration of 18 months, which included regular PSA sampling, 3T mpMRI, and ultrasound/MR fusion-guided biopsies systematic and targeted at the site of the focal treatment. Results: The focal ablation procedure was carried out in an outpatient setting regimen with optimal clinical and biochemical outcomes. No recurrence was detected throughout the follow-up period. Conclusion: TPLA focal treatment effectively manages local recurrences of RT refractory prostate cancer without side-effects or complications. Preservation of quality of life and functional outcomes, along with Advances in knowledge: Our study investigated TPLA as a salvage treatment for low-risk recurrent prostate cancer after RT, demonstrating its tolerability, feasibility, and effectiveness.

Identifiers

PMID37942495
PMCPMC10630978
OpenAlexW4387738396

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.